**What is already known about the topic?**

-   Patients with advanced disease may present a wish to hasten death (WTHD) as a reaction to suffering.

-   Data for the prevalence of a WTHD show considerable variability (between 1.5% and 38%).

-   This wide variability may reflect not only a diversity of patient populations but also differences in the construct assessed, as well as in other aspects related to the characteristics of the instruments used.

**What this paper adds?**

-   We identified seven different instruments (five plus two modifications) that have been used to assess the WTHD in adults with advanced disease. However, not all of them have been subject to an analysis of their validity and reliability.

-   The Schedule of Attitudes toward Hastened Death (SAHD) and the Desire for Death Rating Scale (DDRS), with its modifications, are the most widely used instruments, although in both cases limited information is available regarding their measurement properties.

-   The DDRS can readily be used in clinical practice, whereas the characteristics of the SAHD, especially its length and direct wording of items, may mean it is more suited to research.

**Implications for practice, theory or policy**

-   This study may help clinicians and researchers to choose the tool for assessing the WTHD that is best suited to their goals.

-   More studies are needed to examine the unknown measurement properties of the two most widely used instruments.

-   An understanding of how the different instruments have been used, as well as of the construct of the WTHD on which each one is based, is crucial when it comes to deciding which instrument to use in a given context.

-   Gathering patients' own views about how they would like clinicians to explore this issue could help in developing an instrument that is better suited to the needs of patients.

Introduction {#section7-0269216316669867}
============

The wish to hasten death (WTHD) in the context of advanced disease is a complex phenomenon of growing interest among clinicians and researchers. Research to date has focused particularly on the multiple factors that may trigger such a wish,^[@bibr1-0269216316669867][@bibr2-0269216316669867]--[@bibr3-0269216316669867]^ and recent studies^[@bibr4-0269216316669867],[@bibr5-0269216316669867]^ suggest that in advanced patients it emerges as a reaction to suffering. Hence, a WTHD in these patients might be regarded as a red flag for suffering.

The estimated prevalence of the WTHD in patients with advanced disease varies considerably across studies, ranging between 1.5% and 37.8%.^[@bibr1-0269216316669867],[@bibr6-0269216316669867][@bibr7-0269216316669867][@bibr8-0269216316669867][@bibr9-0269216316669867][@bibr10-0269216316669867][@bibr11-0269216316669867][@bibr12-0269216316669867][@bibr13-0269216316669867][@bibr14-0269216316669867][@bibr15-0269216316669867]--[@bibr16-0269216316669867]^ This variability in the published data is likely due to the characteristics of the patient samples studied, as well as to the assessment instruments used. Thus, the highest prevalence rates usually correspond to samples of patients in the advanced or terminal stage of disease,^[@bibr1-0269216316669867],[@bibr11-0269216316669867],[@bibr16-0269216316669867][@bibr17-0269216316669867]--[@bibr18-0269216316669867]^ whereas the lowest rates have been reported in outpatients at various stages of disease or in active treatment.^[@bibr7-0269216316669867],[@bibr12-0269216316669867],[@bibr13-0269216316669867]^ Prevalence rates also vary across studies that have used the same assessment instrument in apparently similar samples, due to the application of different cut-offs for the total score obtained on the instrument.^[@bibr11-0269216316669867],[@bibr19-0269216316669867]^ At all events, comparison of results is hindered mainly by the fact that they are derived from different instruments and often without an explicit theoretical framework in which the concept of the WTHD is clearly defined.

Various methods typically associated with the reporting of health-related patient-reported outcomes (e.g. interviews, schedules, scales and questionnaires, hereafter referred to as 'instruments') have been used to assess the WTHD.^[@bibr1-0269216316669867],[@bibr9-0269216316669867],[@bibr20-0269216316669867][@bibr21-0269216316669867][@bibr22-0269216316669867]--[@bibr23-0269216316669867]^ Two of the most widely used among these instruments are the Desire for Death Rating Scale (DDRS)^[@bibr20-0269216316669867]^ and the Schedule of Attitudes toward Hastened Death (SAHD).^[@bibr21-0269216316669867]^ The DDRS was designed in Canada to assess the WTHD among patients with cancer,^[@bibr20-0269216316669867]^ and it has subsequently been used in several studies. The SAHD was developed in the United States and was initially applied towards the end of the 1990s in patients with HIV/AIDS^[@bibr21-0269216316669867]^ and cancer.^[@bibr24-0269216316669867]^ It has since become the most widely used instrument in the field and has been translated and validated in several languages.^[@bibr13-0269216316669867],[@bibr15-0269216316669867],[@bibr25-0269216316669867][@bibr26-0269216316669867]--[@bibr27-0269216316669867]^

To date, no published study has analysed the different instruments used to assess the WTHD in patients with advanced disease. Consequently, this systematic review aims (a) to identify and analyse the studies that have assessed the WTHD in adult patients with advanced disease, (b) to analyse the characteristics of the different measurement instruments used for this purpose, (c) to evaluate the methodological quality of validation studies that have examined the psychometric properties of instruments for measuring the WTHD and (d) to rate the different instruments according to their reported psychometric properties.

Method {#section8-0269216316669867}
======

Design and data sources {#section9-0269216316669867}
-----------------------

This systematic review and analysis of instruments used to measure the WTHD was conducted in accordance with PRISMA guidelines.^[@bibr28-0269216316669867]^ The search strategy was applied to the CINAHL, PsycINFO, Pubmed and Web of Science databases, from their inception to November 2015.

Eligibility criteria {#section10-0269216316669867}
--------------------

Potential articles were selected by applying the following inclusion criteria: (a) peer-reviewed articles published in English, French or Spanish and (b) articles that mentioned the use of at least one instrument for measuring the WTHD in adult patients with advanced disease and/or who were being cared for in any palliative care facility. There were no restrictions in terms of study design or the type of measurement instrument used to assess the WTHD, since the aim of the review was to identify all the instruments that have been used to date; thus, we included not only instruments or questionnaires designed specifically for this purpose but also other forms of assessment that, among other aspects, sought to evaluate the WTHD. For this review, we excluded studies conducted with a paediatric population or in older people without advanced disease.

Search strategy and article selection {#section11-0269216316669867}
-------------------------------------

The search strategy used a combination of MeSH and free text terms covering three domains: WTHD, measurements and population. [Table 1](#table1-0269216316669867){ref-type="table"} shows the strategy that was finally used. This strategy was adapted to each of the databases.

###### 

Final database search strategy.

![](10.1177_0269216316669867-table1)

  ------ ------------------------------------------------------------- ----------------------
  \#1    'wish to die' \[Text Word\]                                   Wish to hasten death
  \#2    'wish to hasten death' \[Text Word\]                          
  \#3    'wish for hastening death' \[Text Word\]                      
  \#4    'desire to die' \[Text Word\]                                 
  \#5    'desire for early death' \[Text Word\]                        
  \#6    'want to die' \[Text Word\]                                   
  \#7    'desire for death' \[Text Word\]                              
  \#8    \#1 OR \#2 OR \#3 OR \#4 OR \#5 OR \#6 OR \#7                 
  \#9    'tool' \[Text Word\]                                          Measurements
  \#10   'instrument' \[Text Word\]                                    
  \#11   'scale' \[Text Word\]                                         
  \#12   'validation' \[Text Word\]                                    
  \#13   'measuring' \[Text Word\]                                     
  \#14   'evaluation' \[Text Word\]                                    
  \#15   'validation' \[Text Word\]                                    
  \#16   'assessment' \[Text Word\]                                    
  \#17   \#9 OR \#10 OR \#11 OR \#12 OR \#13 OR \#14 OR \#15 OR \#16   
  \#18   'advanced illness' \[Text Word\]                              Population
  \#19   'palliative care' \[MeSH\]                                    
  \#20   'cancer' \[Text Word\]                                        
  \#21   'chronic illness' \[Text Word\]                               
  \#22   'terminally ill' \[MeSH\]                                     
  \#23   \#18 OR \#19 OR \#20 OR \#21 OR \#22                          
  \#24   \#8 AND \#18 AND \#23                                         
  ------ ------------------------------------------------------------- ----------------------

The search results were imported into a reference management software package, at which stage any duplicates were removed. The first author (M.B.-P.) independently selected potential articles, with the selection being verified by another researcher (C.M.-R.), who is an experienced systematic reviewer. The retrieved citations were sifted in three stages, first by title, second by abstract and finally by full text. Studies were omitted if they did not meet the inclusion criteria, with any disagreements being resolved by discussion between all researchers. [Figure 1](#fig1-0269216316669867){ref-type="fig"} illustrates the search process.

![PRISMA flow diagram for study selection.\
\*Reasons for exclusion: (a) language of the publication (*n* = 1), (b) not peer-reviewed journal (*n* = 8), (c) the study did not include any WTHD measurement (*n* = 36), (d) the study is focused on the paediatric population (*n* = 1), (e) the target population is not advanced disease or palliative care (*n* = 3) and (f) measurement of the WTHD was based on the report of informants such as relatives or health professionals (*n* = 1).](10.1177_0269216316669867-fig1){#fig1-0269216316669867}

Data extraction {#section12-0269216316669867}
---------------

Two researchers (M.B.-P. and C.M.-R.) used data extraction sheets to extract data from the studies included in the review and then analysed and compared these data.^[@bibr29-0269216316669867]^ Once again, any disagreements were resolved by consensus among all the researchers. The following descriptive data were extracted: authors, year of publication, country in which the study was conducted, instrument used to measure the WTHD and the aim(s) of the study. The following study characteristics were also extracted: design, mean and standard deviation reported for the WTHD, setting and population.

Quality assessment {#section13-0269216316669867}
------------------

Two assessments of quality were performed, one for the methodological quality of studies reporting the measurement properties of specific instruments and another to rate the reported psychometric properties of the instruments used.

The first of these assessments applied the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist.^[@bibr30-0269216316669867]^ The COSMIN checklist categorises the information provided by a study into 12 boxes, 9 of which contain standards for how each measurement property should be assessed (internal consistency, reliability, measurement error, content validity, structural validity, hypothesis testing, cross-cultural validity, criterion validity and responsiveness). Each box contains between 5 and 18 items, with each item being scored on a 4-point rating scale (poor to excellent).^[@bibr31-0269216316669867]^

As regards the second assessment, the quality of an instrument's psychometric properties was evaluated using the criteria proposed by Terwee et al.,^[@bibr32-0269216316669867]^ which enable each measurement property to be rated as positive (+), negative (−), indeterminate (?) or no information available (0).

In order to ensure consistency in the application of COSMIN criteria for evaluating studies^[@bibr31-0269216316669867]^ and instruments,^[@bibr32-0269216316669867]^ two researchers (M.B.-P. and C.M.-R.) applied the criteria independently. Any disagreements were then resolved through team discussion.

Data analysis and synthesis of results {#section14-0269216316669867}
--------------------------------------

For the extraction and analysis of data from the studies included, we created a spreadsheet in which the information was categorised according to the content and evaluation of the instruments used to measure the WTHD. The characteristics of the studies, as well as the evaluation of methodological quality and the quality rating of psychometric properties, were analysed and summarised in the form of a narrative summary.

Results {#section15-0269216316669867}
=======

After application of the aforementioned inclusion criteria, a total of 50 articles were included in the review (see [Figure 1](#fig1-0269216316669867){ref-type="fig"}, which also describes the main reasons for exclusion of records). No study was eliminated on the basis of quality criteria.

Characteristics of the included articles {#section16-0269216316669867}
----------------------------------------

[Table 2](#table2-0269216316669867){ref-type="table"} shows the main characteristics of the 50 articles included. They were all published in the last 20 years, with an even spread across the two decades. The largest proportion of studies, 34% of the total (*n* = 17), were carried out in the United States, followed by 16% in Canada (*n* = 8), 16% in Greece (*n* = 8) and 10% in Australia (*n* = 5).

###### 

Descriptive data for the included articles.

![](10.1177_0269216316669867-table2)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year, first author, country                                                                                       Instrument                                    Study design                                     Population                                        Setting                                              Sample (final)                               Percentage of total patient population that was eligible^[a](#table-fn2-0269216316669867){ref-type="table-fn"}^   Percentage of eligible^[b](#table-fn3-0269216316669867){ref-type="table-fn"}^ participants included   Mean score for WTHD ± SD \[range scored\]                                                              Cut-off used by authors (percentage of high WTHD according to cut-off)   Purpose of measuring the WTHD in the article included in the review
  ----------------------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------ ------------------------------------------------- ---------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------ ---------------------------------------------------------------------
  1995, Chochinov,^[@bibr20-0269216316669867]^ Canada                                                               DDRS                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 200                                    23.0%                                                                                                             92.6%                                                                                                 Not reported                                                                                           ⩾4 (8.5%)                                                                MP

  1999, Rosenfeld,^[@bibr21-0269216316669867]^ USA                                                                  SAHD\                                         Cross-sectional                                  HIV/AIDS patients                                 Home care; palliative care hospice                   *n* = 195                                    Not reported                                                                                                      Not reported                                                                                          3.05 ± 3.80\                                                                                           ⩾7 (12%)\                                                                VAL
                                                                                                                    DDRS (both instruments in only 47 patients)                                                                                                                                                                                                                                                                                                                                                                                                                                1.19 ± 1.65                                                                                            ⩾11 (6%)\                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ⩾3 (15%)                                                                 

  2000,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Breitbart,^[@bibr6-0269216316669867]^ USA            SAHD                                          Prospective                                      Terminally ill cancer patients                    Palliative care unit                                 *n* = 92                                     22%                                                                                                               59.7%                                                                                                 4.76 ± 4.3\                                                                                            ⩾10 (17%)                                                                MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \[0--16\]                                                                                                                                                                       

  2000, Rabkin,^[@bibr48-0269216316669867]^ USA                                                                     SAHD                                          Cross-sectional                                  ALS patients                                      ALS centre                                           *n* = 56 patients and 31 caregivers          Not reported                                                                                                      Not reported                                                                                          3.7 ± 3.4                                                                                              Not reported                                                             OUT

  2000,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Rosenfeld,^[@bibr24-0269216316669867]^ USA           SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 92                                     Not reported                                                                                                      59.7%                                                                                                 4.76 ± 4.3                                                                                             ⩾10 (16.3%)                                                              VAL

  2002, Chochinov,^[@bibr37-0269216316669867]^ Canada                                                               DDRS                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 213                                    Not reported                                                                                                      57.7%                                                                                                 0.54 ± 0.81 (patients with intact sense of dignity)\                                                   Not reported                                                             OUT
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.3 ± 1.3 (patients with fractured sense of dignity)                                                                                                                            

  2002, Kelly,^[@bibr1-0269216316669867]^ Australia                                                                 Modified DDRS                                 Mixed methods: qualitative and cross-sectional   Terminally ill cancer patients                    Hospice and home palliative care                     *n* = 72                                     Not reported                                                                                                      Not reported                                                                                          Not reported                                                                                           ⩾5 (22.2%)                                                               MP/VAL

  2002, Tiernan,^[@bibr22-0269216316669867]^ Ireland                                                                Four items designed by authors                Cross-sectional                                  Terminally ill cancer patients                    Hospice                                              *n* = 142                                    50.3%                                                                                                             Not reported                                                                                          Not reported                                                                                           Score 2 or 3 on any question (1.4%)                                      MP

  2003, Jones,^[@bibr7-0269216316669867]^ Canada                                                                    SAHD                                          Cross-sectional                                  Cancer patients                                   Cancer centre                                        *n* = 224                                    60.2%                                                                                                             77%                                                                                                   Not reported                                                                                           ⩾10 (2%)                                                                 MP

  2003, Kelly,^[@bibr43-0269216316669867]^ Australia                                                                Modified DDRS                                 Cross-sectional                                  Terminally ill cancer patients                    Palliative care service                              *n* = 256                                    19.3%                                                                                                             49%                                                                                                   Not reported                                                                                           ⩾5 (14%)                                                                 MP

  2003, Kelly,^[@bibr44-0269216316669867]^ Australia                                                                Modified DDRS                                 Mixed methods                                    Doctors and terminally ill cancer patient pairs   Hospice unit                                         *n* = 24                                     Not reported                                                                                                      62%                                                                                                   Not reported                                                                                           ⩾5 (25%)                                                                 MP

  2003, McClain,^[@bibr49-0269216316669867]^ USA                                                                    SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care hospital                             *n* = 160                                    4.9%                                                                                                              26.5%                                                                                                 Not reported                                                                                           Not reported                                                             OUT

  2003,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Pessin,^[@bibr8-0269216316669867]^ USA               SAHD                                          Cross-sectional                                  Advanced AIDS patients                            Long-term care treatment facility                    *n* = 128                                    68.4%                                                                                                             Not reported                                                                                          2.8 ± 3.0                                                                                              ⩾7 (10%)                                                                 MP

  2004,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Kelly,^[@bibr45-0269216316669867]^ Australia         Modified DDRS                                 Cross-sectional                                  Doctors and terminally ill cancer patient pairs   Palliative care service                              *n* = 252                                    58%                                                                                                               58%                                                                                                   Not reported                                                                                           ⩾5 (14%)                                                                 MP

  2004, Kissane,^[@bibr62-0269216316669867]^ Australia                                                              SAHD                                          Cross-sectional                                  Advanced cancer patients                          Palliative care or psycho-oncology clinics           *n* = 100                                    Not reported                                                                                                      61.3%                                                                                                 Not reported                                                                                           Not reported                                                             OUT

  2004, McClain,^[@bibr50-0269216316669867]^ USA                                                                    SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care hospital                             *n* = 276                                    Not reported                                                                                                      Not reported                                                                                          3.5 ± 3.7 (belief in afterlife)\                                                                       Not reported                                                             OUT
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               5.4 ± 4.6 (no belief in afterlife)\                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3.9 ± 4.3 (not sure)                                                                                                                                                            

  2004,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Mystakidou,^[@bibr56-0269216316669867]^ Greece       SAHD                                          Cross-sectional                                  Advanced cancer patients                          Palliative care unit                                 *n* = 120                                    62.8%                                                                                                             81%                                                                                                   2.9 ± 3.70                                                                                             High ⩾7 (8.3%)\                                                          MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Strong ⩾11 (5%)                                                          

  2004,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Mystakidou,^[@bibr25-0269216316669867]^ Greece       SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 120                                    62.8%                                                                                                             81%                                                                                                   2.9 ± 3.70                                                                                             High ⩾7 (8.3%)\                                                          VAL
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Strong ⩾11 (5%)                                                          

  2004, Wilson,^[@bibr33-0269216316669867]^ Canada                                                                  SISC                                          Cross-sectional                                  Advanced cancer patients                          Palliative care unit                                 *n* = 69                                     Not reported                                                                                                      Not reported                                                                                          2.81 ± 2.01 patients with a depressive disorder and 0.51 ± 0.91 patients without depressive disorder   ⩾3 (18.8%)                                                               VAL

  2005, Albert,^[@bibr35-0269216316669867]^ USA                                                                     SAHD and two visual analogue scales           Prospective                                      Advanced ALS                                      MDA/ALS Research Centre Hospices                     *n* = 80                                     Not reported                                                                                                      63%                                                                                                   Patients who expressed wish to die according to VAS, scored 12.6 on SAHD                               Not reported (18.9%)                                                     MP

  2005, Chochinov,^[@bibr46-0269216316669867]^ Canada and Australia                                                 SISC                                          Cross-sectional                                  End-stage cancer patients                         Inpatients and home-based palliative care services   *n* = 100                                    55.2%                                                                                                             78%                                                                                                   Not reported                                                                                           Not reported                                                             OUT

  2005,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Chochinov,^[@bibr38-0269216316669867]^ Canada        DDRS                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 189                                    51.2%                                                                                                             64%                                                                                                   Not reported                                                                                           Not reported                                                             OUT

  2005,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Mystakidou,^[@bibr57-0269216316669867]^ Greece       SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 120                                    77.5%                                                                                                             81%                                                                                                   2.9 ± 3.70                                                                                             High ⩾7 (8.3%)\                                                          MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Strong ⩾11 (5%)                                                          

  2005,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Mystakidou,^[@bibr58-0269216316669867]^ Greece       SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 120                                    Not reported                                                                                                      81%                                                                                                   2.9 ± 3.70                                                                                             High ⩾7 (8.3%)\                                                          MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Strong ⩾11 (5%)                                                          

  2005, O'Mahony,^[@bibr10-0269216316669867]^ USA                                                                   DDRS                                          Cohort study                                     Patients in active antineoplasic treatment        Pain and palliative care service                     *n* = 131                                    22.5%                                                                                                             38%                                                                                                   0.84 (baseline)\                                                                                       No cut-off (26.6% baseline and follow-up)                                MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.38 (follow-up)                                                                                                                                                                

  2006, Mystakidou,^[@bibr11-0269216316669867]^ Greece                                                              SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 106                                    56.1%                                                                                                             87.6%                                                                                                 Not reported                                                                                           High ⩾7 or strong ⩾11 (28%)                                              MP

  2006, Ransom,^[@bibr51-0269216316669867]^ USA                                                                     SAHD                                          Longitudinal                                     Advanced cancer patients                          Cancer centre                                        *n* = 60 couples (patients and caregivers)   Not reported                                                                                                      21.2%                                                                                                 2.53 ± 1.86 (T1)\                                                                                      ⩾10 (0%; T1)\                                                            MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               2.55 ± 2.30 (T2)                                                                                       ⩾10 (3.3%; T2)                                                           

  2006,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Rosenfeld,^[@bibr41-0269216316669867]^ USA           SAHD and DDRS                                 Cross-sectional                                  Advanced AIDS patients                            Palliative care facility                             *n* = 372                                    27.0%                                                                                                             87.1%                                                                                                 2.9 ± 3.3 (SAHD)\                                                                                      SAHD ⩾ 10 (4.6%)\                                                        MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0.7 ± 1.1 (DDRS)                                                                                       DDRS ⩾ 3 (6.5%)                                                          

  2007,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Mystakidou,^[@bibr59-0269216316669867]^ Greece       SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 102                                    Not reported                                                                                                      81.6%                                                                                                 2.9 ± 3.70                                                                                             ⩾7 (3.9%)\                                                               MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ⩾11 (8.8%)                                                               

  2007, Rodin,^[@bibr12-0269216316669867]^ Canada                                                                   SAHD                                          Cross-sectional                                  Outpatient metastatic cancer patients             Oncology hospital                                    *n* = 326                                    32.1                                                                                                              44.6%                                                                                                 1.7 ± 2.2                                                                                              ⩾10 (1.5%)                                                               MP

  2008, Mystakidou,^[@bibr19-0269216316669867]^ Greece                                                              SAHD                                          Cross-sectional                                  Advanced cancer patients                          Palliative care unit                                 *n* = 91                                     46.9%                                                                                                             81.2%                                                                                                 3.92 ± 4.91                                                                                            ⩾7 (22%)                                                                 MP

  2008, Mystakidou,^[@bibr17-0269216316669867]^ Greece                                                              SAHD                                          Cross-sectional                                  Advanced cancer patients                          Palliative care unit                                 *n* = 112                                    Not reported                                                                                                      81.1%                                                                                                 Not reported                                                                                           Not reported                                                             OUT

  2009, Olden,^[@bibr52-0269216316669867]^ USA                                                                      SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care facility                             *n* = 422                                    Not reported                                                                                                      Not reported                                                                                          Not reported                                                                                           Not reported                                                             OUT

  2009, Rodin,^[@bibr60-0269216316669867]^ Canada                                                                   SAHD                                          Cross-sectional                                  Advanced cancer patients                          Oncology hospital                                    *n* = 406                                    Not reported                                                                                                      Not reported                                                                                          1.74 ± 2.16                                                                                            Not reported                                                             MP

  2010, Breitbart,^[@bibr53-0269216316669867]^ USA                                                                  SAHD                                          Randomised controlled trial                      Advanced cancer patients                          Outpatient unit of cancer hospital                   *n* = 90                                     Not reported                                                                                                      Not reported                                                                                          3.64 (meaning-centred group psychotherapy)\                                                            Not reported                                                             OUT
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               4.0 (Supportive group therapy)                                                                                                                                                  

  2010, Breitbart,^[@bibr16-0269216316669867]^ USA                                                                  SAHD and DDRS                                 Prospective                                      Advanced AIDS patients                            Palliative care unit                                 *n* = 372                                    27.07%                                                                                                            87.1%                                                                                                 Not reported                                                                                           SAHD ⩾ 10; DDRS ⩾ 3 (37.8%)                                              MP

  2010,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ O'Mahony,^[@bibr40-0269216316669867]^ USA            DDRS                                          Cohort study                                     Patients in active antineoplasic treatment        Pain and palliative care service                     *n* = 64                                     Not reported                                                                                                      55.1%                                                                                                 0.84 ± 1.59 (baseline)\                                                                                Not reported                                                             MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.38 ± 2.13 (follow-up)                                                                                                                                                         

  2010,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Voltz,^[@bibr61-0269216316669867]^ Germany           SAHD                                          Cross-sectional                                  Advanced cancer patients                          Palliative care unit                                 *n* = 18                                     15%                                                                                                               31%                                                                                                   Not reported                                                                                           Not reported                                                             MP

  2011, Chochinov,^[@bibr47-0269216316669867]^ Canada, Australia and USA                                            SISC                                          Randomised controlled trial                      Terminally ill patients                           Palliative care (hospice or home)                    *n* = 326                                    21.5%                                                                                                             36.9%                                                                                                 0.53 ± 0.88 (dignity therapy)\                                                                         Not reported                                                             OUT
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0.65 ± 129 (standard palliative care)\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0.68 ± 1.18 (client-centred care)                                                                                                                                               

  2011,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Price,^[@bibr39-0269216316669867]^ United Kingdom    DDRS                                          Cross-sectional with 4-week follow-up            Advanced disease patients                         Hospice                                              *n* = 300                                    Not reported                                                                                                      40%                                                                                                   Not reported                                                                                           ⩾4 (3.7%, T1)\                                                           MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ⩾4 (3.3%, T2)                                                            

  2011,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Rayner,^[@bibr18-0269216316669867]^ United Kingdom   DDRS                                          Cross-sectional                                  Palliative patients                               Palliative care hospice                              *n* = 300                                    15.7%                                                                                                             40%                                                                                                   Not reported                                                                                           No cut-off (35.6%)                                                       OUT

  2011, Shim,^[@bibr13-0269216316669867]^ Korea                                                                     SAHD                                          Cross-sectional                                  Cancer patients currently in treatment            Cancer hospital                                      *n* = 131                                    46.1                                                                                                              69.6%                                                                                                 2.74 ± 2.34                                                                                            ⩾10 (1.7%)                                                               MP/VAL

  2013, Julião,^[@bibr42-0269216316669867]^ Portugal                                                                DDRS                                          Cross-sectional                                  Terminally ill patients                           Palliative care unit                                 *n* = 75                                     45.4%                                                                                                             Not reported                                                                                          Not reported                                                                                           ⩾4 (20%)                                                                 MP

  2014, Rosenfeld,^[@bibr54-0269216316669867]^ USA                                                                  SAHD                                          Longitudinal                                     Terminally ill cancer patients                    Palliative care hospital                             *n* = 128                                    8.0%                                                                                                              12.9%                                                                                                 1.65 ± 1.4 (low trajectory)\                                                                           ⩾7 (17.2%; at both time points)                                          MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               10.00 ± 2.9 (rising trajectory)\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               4.60 ± 1.3 (falling)\                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               11.13 ± 2.9 (high)                                                                                                                                                              

  2014, Stutzki,^[@bibr34-0269216316669867]^ Switzerland and Germany                                                Designed by authors                           Longitudinal                                     ALS patients                                      ALS centre                                           *n* = 66 patients and 62 caregivers          22.6%                                                                                                             50.3%                                                                                                 Not reported                                                                                           ⩾1 (14% baseline;\                                                       MP
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      16% follow-up)                                                           

  2014, Villavicencio,^[@bibr15-0269216316669867]^ Spain                                                            SAHD                                          Cross-sectional                                  Advanced cancer patients                          Palliative care unit                                 *n* = 101                                    14%                                                                                                               35.4%                                                                                                 4.99 ± 5.32                                                                                            ⩾10 (16.8%)                                                              VAL

  2015, Breitbart,^[@bibr55-0269216316669867]^ USA                                                                  SAHD                                          Randomised controlled trial                      Advanced cancer patients                          Outpatient unit of cancer centre                     *n* = 253                                    7.6%                                                                                                              Not reported                                                                                          2.30 ± 3.34 (meaning-centred psychotherapy)\                                                           Not reported                                                             OUT
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.89 ± 3.06 (supportive group\                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               psychotherapy)                                                                                                                                                                  

  2015,^[c](#table-fn4-0269216316669867){ref-type="table-fn"}^ Galushko,^[@bibr26-0269216316669867]^ Germany        SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 92                                     10.5%                                                                                                             Not reported                                                                                          5.09 ± 3.71                                                                                            ⩾10 (12%)                                                                VAL

  2016, Wang,^[@bibr27-0269216316669867]^ China                                                                     SAHD                                          Cross-sectional                                  Terminally ill cancer patients                    Palliative care unit                                 *n* = 85                                     Not reported                                                                                                      Not reported                                                                                          5.56 ± 5.19                                                                                            Not reported                                                             MP

  2016, Wilson,^[@bibr23-0269216316669867]^ Canada                                                                  SISC                                          Cross-sectional                                  Advanced cancer patients                          Palliative care unit                                 *n* = 377                                    Not reported                                                                                                      Not reported                                                                                          Not reported                                                                                           ⩾3 (12.2%)                                                               MP
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

WTHD: wish to hasten death; SD: standard deviation; MP: main purpose; OUT: outcome variable; VAL: validation; DDRS: Desire for Death Rating Scale; SAHD: Schedule of Attitudes toward Hastened Death; SISC: Structured Interview for Symptoms and Concerns.

Percentage of total patient population regarded as eligible and who were invited to participate.

Percentage of eligible patients included in the data analysis.

Part of a larger study.

In terms of their design, the majority (*n* = 37) were cross-sectional studies.

Regarding participants, 48 studies focused directly on patients, while the remaining 2 gathered data from doctor-terminally ill patient pairs. With respect to the clinical diagnosis, 78% of studies (*n* = 39) involved patients with cancer, 8% (*n* = 4) concerned patients with HIV/AIDS and 6% (*n* = 3) patients with amyotrophic lateral sclerosis (ALS).

The analysis of study aims revealed that 58% of the studies included in the review (*n* = 29) had the assessment of the WTHD as their main purpose (MP), 26% (*n* = 13) included the assessment of the WTHD as one among other outcome variables (OUT) and 16% (*n* = 8) were instrument validation studies (VAL).

Characteristics of the instruments used to assess the WTHD {#section17-0269216316669867}
----------------------------------------------------------

Given that, for the purposes of the present review, we considered modifications of an original instrument as constituting a separate measure, the analysis identified seven different instruments for analysing the WTHD.^[@bibr1-0269216316669867],[@bibr20-0269216316669867][@bibr21-0269216316669867]--[@bibr22-0269216316669867],[@bibr33-0269216316669867][@bibr34-0269216316669867]--[@bibr35-0269216316669867]^ Adaptations and validations of instruments in other languages were not considered as separate measures. These instruments consisted of scales,^[@bibr1-0269216316669867],[@bibr20-0269216316669867],[@bibr33-0269216316669867]^ questionnaires,^[@bibr21-0269216316669867],[@bibr34-0269216316669867]^ a series of questions^[@bibr22-0269216316669867]^ and the use of visual analogue scales.^[@bibr35-0269216316669867]^ [Table 3](#table3-0269216316669867){ref-type="table"} shows the main characteristics of each kind of instrument. The number of items or questions in these instruments varies between 1 and 20. Only one of the instruments^[@bibr21-0269216316669867]^ has been subjected to an explicit process of transcultural adaptation and validation, involving the study of its psychometric properties, in order to develop versions in other languages. In the remainder of this section, we describe the different instruments identified, in chronological order according to the year of publication of the original study.

###### 

Characteristics of the different instruments used to assess the WTHD in the included articles.

![](10.1177_0269216316669867-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Instrument                               First author, year                            Kind of assessment   Language in which available             Dimensions and Cronbach's alpha   Items/categories                                                        Response                  Range       Cut-off score (original study)
  ---------------------------------------- --------------------------------------------- -------------------- --------------------------------------- --------------------------------- ----------------------------------------------------------------------- ------------------------- ----------- --------------------------------
  DDRS                                     Chochinov, 1995^[@bibr20-0269216316669867]^   Clinician-rated      English                                 --                                1 screening item plus a further 3 items if the first item is endorsed   6-point rating scale      \[0--6\]    ⩾4

  SAHD                                     Rosenfeld, 1999^[@bibr21-0269216316669867]^   Self-report\         English^[@bibr21-0269216316669867]^\    Unidimensional, 0.89\             20 items                                                                True/false                \[0--20\]   0--3 Low\
                                                                                         Clinician-rated      German^[@bibr26-0269216316669867]^\     Bidimensional, 0.71\                                                                                                                            \>3 to \<10 Moderate\
                                                                                                              Greece^[@bibr25-0269216316669867]^\     Unidimensional, 0.89\                                                                                                                           ⩾7 High\
                                                                                                              Korean^[@bibr13-0269216316669867]^\     Unidimensional, 0.66\                                                                                                                           ⩾11 Strong
                                                                                                              Spanish^[@bibr15-0269216316669867]^\    Unidimensional, 0.92\                                                                                                                           
                                                                                                              Taiwanese^[@bibr27-0269216316669867]^   Not reported                                                                                                                                    

  Modified DDRS                            Kelly, 2002^[@bibr1-0269216316669867]^        Clinician-rated      English                                 Unidimensional, 0.86              6 items                                                                 5-point Likert response   \[0--24\]   0 No wish\
                                                                                                                                                                                                                                                                                                      ⩾1 to ⩽4 Moderate\
                                                                                                                                                                                                                                                                                                      ⩾5 High

  Questions developed by authors           Tiernan, 2002^[@bibr22-0269216316669867]^     Clinician-rated      English                                                                   4 items                                                                 0--3 rating scale         \[0--12\]   Score 2 or 3 on any question

  Modified DDRS introduced into the SISC   Wilson, 2004^[@bibr33-0269216316669867]^      Clinician-rated      English                                 --                                1 screening item and a further 3 items if the first item is endorsed    0--6 point rating         \[0--6\]    0 No wish\
                                                                                                                                                                                                                                                                                                      3 Moderate\
                                                                                                                                                                                                                                                                                                      6 Extreme

  Visual analogue scale                    Albert, 2005^[@bibr35-0269216316669867]^      Clinician-rated      English                                 --                                2 visual analogue questions                                             1--10 point rating        \[1--10\]   ⩾8

  Questions developed by authors           Stutzki, 2014^[@bibr34-0269216316669867]^     Clinician-rated      German                                                                    1 question about the WTHD\                                              Numerical rating scale\   \[0--10\]   ⩾1
                                                                                                                                                                                        7 questions about plans and ideation                                    Yes/No                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DDRS: Desire for Death Rating Scale; SAHD: Schedule of Attitudes toward Hastened Death; SISC: Structured Interview for Symptoms and Concerns.

The first instrument for assessing the WTHD was developed by Chochinov et al.^[@bibr20-0269216316669867]^ in a sample of Canadian patients with cancer, concerned by the fact that euthanasia and assisted suicide had become prominent medical and social issues. This instrument, the DDRS, consists of a screening question ('Do you ever wish that your illness would progress more rapidly so that your suffering could be over sooner?') which, if endorsed, is followed by a further three questions that form a semi-structured interview. The authors were inspired by the diagnostic interview of the Schedule for Affective Disorder and Schizophrenia (SADS)^[@bibr36-0269216316669867]^ to design the DDRS. As in the SADS protocol, the interviewer is required to rate the severity of the psychiatric symptoms on 6- or 7-point scales. In the same way, the DDRS enables clinicians to rate patients along a 6-point scale and it has been used in Canada,^[@bibr20-0269216316669867],[@bibr37-0269216316669867],[@bibr38-0269216316669867]^ the United Kingdom,^[@bibr18-0269216316669867],[@bibr39-0269216316669867]^ the United States^[@bibr10-0269216316669867],[@bibr16-0269216316669867],[@bibr21-0269216316669867],[@bibr40-0269216316669867],[@bibr41-0269216316669867]^ and Portugal.^[@bibr42-0269216316669867]^ To our knowledge, the psychometric properties of the original scale have not been reported.

Kelly et al.^[@bibr1-0269216316669867]^ modified the DDRS and produced a 6-item scale whose psychometric properties have been examined. These authors replaced the original scale item that asks patients whether they have ever expressed a desire to hasten death with two separate items that specified the person with whom such a desire had been discussed, namely, with family/friends or with a doctor/nurse. They also added a new item that specifically enquired 'Have you ever asked a doctor or nurse to do something that might help end your life?'. Each item on this modified scale is rated using a 5-point Likert scale (from 0 to 4), such that the total score ranges from 0 to 24. To date, this modified version of the DDRS has been used in four studies.^[@bibr1-0269216316669867],[@bibr43-0269216316669867][@bibr44-0269216316669867]--[@bibr45-0269216316669867]^

Wilson et al.^[@bibr33-0269216316669867]^ subsequently incorporated a slightly modified version of the DDRS into a broader assessment schedule, the Structured Interview for Symptoms and Concerns (SISC). This interview explores common issues of clinical relevance in the palliative care context, covering physical and psychosocial symptoms. The latter include the desire or WTHD, the frequency and intensity of which is rated on a 6-point scale (from 0 to 6). The SISC has been used to assess the WTHD in three studies.^[@bibr23-0269216316669867],[@bibr46-0269216316669867],[@bibr47-0269216316669867]^

The cut-off used in studies that have applied the DDRS differs across researchers and/or instrument versions. For their modified version, Kelly et al.^[@bibr1-0269216316669867]^ assigned a cut-off ⩾5 (over a possible range of 0--24) as indicative of a 'high' WTHD.^[@bibr1-0269216316669867],[@bibr43-0269216316669867][@bibr44-0269216316669867]--[@bibr45-0269216316669867]^ Wilson and colleagues^[@bibr23-0269216316669867],[@bibr33-0269216316669867]^ established a cut-off ⩾3 over a possible range of 0--6, whereas studies that have used the original DDRS adopt cut-off scores of ⩾3^[@bibr16-0269216316669867],[@bibr21-0269216316669867],[@bibr41-0269216316669867]^ or ⩾4^[@bibr20-0269216316669867],[@bibr39-0269216316669867],[@bibr42-0269216316669867]^ over a possible range of 0--6 (see [Table 2](#table2-0269216316669867){ref-type="table"}).

The prevalence of the WTHD in studies that used the DDRS and which report this figure ranges between 3% and 35%. In those studies that applied the original DDRS to patients with advanced and/or terminal disease in the palliative care context, the percentage of patients reporting a WTHD ranges between 6.5% and 15% with a cut-off ⩾3,^[@bibr21-0269216316669867],[@bibr41-0269216316669867]^ and between 3.3% and 20% with a cut-off ⩾4.^[@bibr20-0269216316669867],[@bibr39-0269216316669867],[@bibr42-0269216316669867]^ In the studies by Kelly and colleagues^[@bibr1-0269216316669867],[@bibr43-0269216316669867][@bibr44-0269216316669867]--[@bibr45-0269216316669867]^ using the modified version of the DDRS, between 14% and 25% of patients expressed a WTHD (cut-off ⩾5), whereas those studies that have applied the SISC (cut-off ⩾3) report percentages between 12.2% and 18.8%^[@bibr23-0269216316669867],[@bibr33-0269216316669867]^ (see [Table 2](#table2-0269216316669867){ref-type="table"}).

The other major instrument for assessing the WTHD is the SAHD, developed by Rosenfeld et al.^[@bibr21-0269216316669867]^ This is a self-report questionnaire (although some adaptations have treated and used it as a clinician-rated measure) containing 20 true/false items, the total score ranging between 0 and 20. The SAHD was originally validated in the United States in a sample of patients with HIV/AIDS^[@bibr21-0269216316669867]^ and then by the same authors 1 year later in patients with far-advanced cancer.^[@bibr24-0269216316669867]^ Transcultural adaptations and validations of the SAHD have since been conducted in Greece,^[@bibr25-0269216316669867]^ South Korea,^[@bibr13-0269216316669867]^ Spain^[@bibr15-0269216316669867]^ and Germany.^[@bibr26-0269216316669867]^ The instrument has also been used in a sample of patients in Taiwan,^[@bibr27-0269216316669867]^ although this Taiwanese version has yet to be formally validated. The different versions of the SAHD have shown adequate internal consistency ([Table 3](#table3-0269216316669867){ref-type="table"}). To date, the instrument has been used in a total of 32 studies: 15 in the United States,^[@bibr6-0269216316669867],[@bibr8-0269216316669867],[@bibr16-0269216316669867],[@bibr21-0269216316669867],[@bibr24-0269216316669867],[@bibr35-0269216316669867],[@bibr41-0269216316669867],[@bibr48-0269216316669867][@bibr49-0269216316669867][@bibr50-0269216316669867][@bibr51-0269216316669867][@bibr52-0269216316669867][@bibr53-0269216316669867][@bibr54-0269216316669867]--[@bibr55-0269216316669867]^ 8 in Greece,^[@bibr11-0269216316669867],[@bibr17-0269216316669867],[@bibr19-0269216316669867],[@bibr25-0269216316669867],[@bibr56-0269216316669867][@bibr57-0269216316669867][@bibr58-0269216316669867]--[@bibr59-0269216316669867]^ 3 in Canada,^[@bibr7-0269216316669867],[@bibr12-0269216316669867],[@bibr60-0269216316669867]^ 2 in Germany^[@bibr26-0269216316669867],[@bibr61-0269216316669867]^ and 1 in Australia,^[@bibr62-0269216316669867]^ South Korea,^[@bibr13-0269216316669867]^ Spain^[@bibr15-0269216316669867]^ and Taiwan.^[@bibr27-0269216316669867]^ In 10 studies,^[@bibr6-0269216316669867],[@bibr7-0269216316669867],[@bibr12-0269216316669867],[@bibr13-0269216316669867],[@bibr15-0269216316669867],[@bibr16-0269216316669867],[@bibr24-0269216316669867],[@bibr26-0269216316669867],[@bibr41-0269216316669867],[@bibr51-0269216316669867]^ the authors applied a cut-off ⩾10 as indicating a high WTHD. In all, 4 studies^[@bibr8-0269216316669867],[@bibr11-0269216316669867],[@bibr19-0269216316669867],[@bibr54-0269216316669867]^ used a cut-off ⩾7, 6 used two cut-offs (⩾7 and ⩾11)^[@bibr21-0269216316669867],[@bibr25-0269216316669867],[@bibr56-0269216316669867][@bibr57-0269216316669867][@bibr58-0269216316669867]--[@bibr59-0269216316669867]^ and 12 studies^[@bibr17-0269216316669867],[@bibr27-0269216316669867],[@bibr35-0269216316669867],[@bibr48-0269216316669867][@bibr49-0269216316669867]--[@bibr50-0269216316669867],[@bibr52-0269216316669867],[@bibr53-0269216316669867],[@bibr55-0269216316669867],[@bibr60-0269216316669867][@bibr61-0269216316669867]--[@bibr62-0269216316669867]^ did not specify a cut-off.

The prevalence of the WTHD in studies that used the SAHD and which report this figure ranges between 1.5% and 28%, although the cut-off applied was not the same in all cases. In those studies that applied the SAHD to patients with advanced disease in the palliative care context, the percentage of patients reporting a WTHD ranges between 3.9% and 28% with a cut-off ⩾7,^[@bibr11-0269216316669867],[@bibr19-0269216316669867],[@bibr25-0269216316669867],[@bibr54-0269216316669867],[@bibr56-0269216316669867][@bibr57-0269216316669867][@bibr58-0269216316669867]--[@bibr59-0269216316669867]^ between 4.6% and 17% with a cut-off ⩾10^[@bibr6-0269216316669867],[@bibr15-0269216316669867],[@bibr24-0269216316669867],[@bibr26-0269216316669867],[@bibr41-0269216316669867]^ and between 5% and 8.8% with a cut-off ⩾11.^[@bibr25-0269216316669867],[@bibr56-0269216316669867][@bibr57-0269216316669867][@bibr58-0269216316669867]--[@bibr59-0269216316669867]^

Tiernan et al.^[@bibr22-0269216316669867]^ drew up four questions to assess the WTHD. The focus of these questions ranged from a passive desire for death to suicidal ideation and a direct reference to assisted suicide: 'I go to sleep hoping that I won't wake up', 'I think of ending my life, but I would not do it', 'I would end my life if I had a chance' and 'I wish the doctors would do something to end my life'. Each statement is scored by the patient using a 4-point Likert-type scale (0--3), such that the total score ranges between 0 and 12. The authors presented these questions to 142 patients with far-advanced cancer receiving palliative care in Ireland, only two of whom reported a strong wish for death. To date, this instrument has not been used in subsequent published studies.

Albert et al.^[@bibr35-0269216316669867]^ conducted a study with patients with ALS in the United States. In addition to using the SAHD to assess the WTHD, they asked patients two questions drawn from a national survey of end-of-life decisions and interest in hastened death. These questions, which were answered using a 10-point VAS, were: 'Have you seriously thought about taking your life?' and 'Have you discussed taking your life or asking your doctor or others to end your life?'. A patient was considered as having expressed a wish for hastened death if he or she had strongly endorsed ending life (defined as a score ⩾8 on the VAS) or had stated that he or she had 'seriously discussed taking (his/her) life or asking (his/her) doctor to end (his/her) life'.

Finally, in a study of patients with ALS in Germany and Switzerland, Stutzki et al.^[@bibr34-0269216316669867]^ used a questionnaire to assess the WTHD and the attitudes of patients (*n* = 66) and caregivers (*n* = 62) towards assisted suicide and the use of life-sustaining measures. The WTHD was explored using the question 'How strong is your current wish to ask others for assistance to end your life prematurely', which patients answered using a numerical rating scale (0--10). The questionnaire also included questions about advance care planning, suicidal ideation, treatment for depression, whether the patient could imagine asking for physician-assisted suicide or euthanasia, and about communicating the WTHD (yes/no). To date, this instrument has not been used in any other studies.

Methodological quality of instrument validation studies {#section18-0269216316669867}
-------------------------------------------------------

We applied COSMIN criteria^[@bibr31-0269216316669867]^ to the eight articles^[@bibr1-0269216316669867],[@bibr13-0269216316669867],[@bibr15-0269216316669867],[@bibr21-0269216316669867],[@bibr24-0269216316669867][@bibr25-0269216316669867]--[@bibr26-0269216316669867],[@bibr33-0269216316669867]^ that reported measurement properties in the context of instrument validation. These studies provided data that enabled us to evaluate a median of five of the nine COSMIN criteria referring to the assessment of measurement properties. No study used item response theory (IRT). [Table 4](#table4-0269216316669867){ref-type="table"} shows detailed COSMIN ratings of measurement properties for each of the eight articles.

###### 

Methodological quality, based on COSMIN criteria,^[@bibr31-0269216316669867]^ of the eight studies reporting measurement properties in the context of instrument validation.

![](10.1177_0269216316669867-table4)

  Instrument      First author, year                                       BOX A: internal consistency   BOX B: reliability                                                                                                       BOX C: measurement error   BOX D: content validity   BOX E: structural validity   BOX F: hypothesis testing   BOX G: cross-cultural validity                                 BOX H: criterion validity   BOX I: responsiveness
  --------------- -------------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------ -------------------------- ------------------------- ---------------------------- --------------------------- -------------------------------------------------------------- --------------------------- -----------------------
  SAHD            Rosenfeld, 1999^[@bibr21-0269216316669867]^              Excellent                                                                                                                                                                         Excellent                 Excellent                    Excellent                                                                                  Good                        
  SAHD            Rosenfeld, 2000^[@bibr24-0269216316669867]^              Good                          Fair^[b](#table-fn9-0269216316669867){ref-type="table-fn"}^                                                                                         Excellent                 Good                         Good                                                                                       Good                        
  Modified DDRS   Kelly, 2002^[@bibr1-0269216316669867]^                   Good                                                                                                                                                                                                        Good                                                                                                                    Poor                        
  SAHD            Mystakidou, 2004^[@bibr25-0269216316669867]^             Excellent                     Excellent^[a](#table-fn8-0269216316669867){ref-type="table-fn"},[b](#table-fn9-0269216316669867){ref-type="table-fn"}^                              Excellent                 Excellent                    Fair                        Good^[c](#table-fn10-0269216316669867){ref-type="table-fn"}^   Good                        
  SISC            Wilson, 2004^[@bibr33-0269216316669867]^                                               Good^[a](#table-fn8-0269216316669867){ref-type="table-fn"},[b](#table-fn9-0269216316669867){ref-type="table-fn"}^                                   Excellent                                              Poor                                                                                       Good                        
  SAHD            Shim, 2011^[@bibr13-0269216316669867]^                   Good                                                                                                                                                                                                                                                                 Fair^[c](#table-fn10-0269216316669867){ref-type="table-fn"}^                               
  SAHD            Villavicencio-Chávez, 2014^[@bibr15-0269216316669867]^   Excellent                                                                                                                                                                         Excellent                 Excellent                    Poor                        Good^[c](#table-fn10-0269216316669867){ref-type="table-fn"}^   Good                        
  SAHD            Galushko, 2015^[@bibr26-0269216316669867]^               Good                                                                                                                                                                              Excellent                 Good                         Fair                        Fair^[c](#table-fn10-0269216316669867){ref-type="table-fn"}^   Good                        

DDRS: Desire for Death Rating Scale; SAHD: Schedule of Attitudes toward Hastened Death; SISC: Structured Interview for Symptoms and Concerns.

Empty space: not applicable. For more detailed information regarding the definitions of psychometric properties and the 4-point scale rating, see the COSMIN website ([www.cosmin.nl](http://www.cosmin.nl)).

Test--retest reliability.

Inter-rater reliability.

Only the quality of the translation procedure was evaluated.

Regarding interpretability, only one study^[@bibr26-0269216316669867]^ reported information about missing items, and none of them detailed the lowest and highest scores possible. Similarly, none of the studies assessed the minimal important change (MIC) or the minimal important difference (MID).

In terms of generalisability, most of the studies involved patients with a mean age between 61 and 66 years. All but one of the eight studies^[@bibr13-0269216316669867]^ were conducted in Western countries.

Rating of psychometric properties {#section19-0269216316669867}
---------------------------------

[Table 5](#table5-0269216316669867){ref-type="table"} shows ratings, based on the criteria of Terwee et al.,^[@bibr32-0269216316669867]^ of the psychometric properties of the instruments described in the aforementioned eight articles. None of the articles provided information relating to the criteria of responsiveness and interpretability. Some criteria, such as reproducibility and floor and ceiling effects, could only be assessed for two^[@bibr25-0269216316669867],[@bibr33-0269216316669867]^ and three articles,^[@bibr21-0269216316669867],[@bibr24-0269216316669867],[@bibr25-0269216316669867]^ respectively.

###### 

Ratings of the reported psychometric properties of validated instruments, based on the criteria of Terwee et al.^[@bibr32-0269216316669867]^

![](10.1177_0269216316669867-table5)

  Instrument      First author, year                                       Content validity   Internal consistency   Criterion validity   Construct validity   Reproducibility (agreement)   Reproducibility (reliability)   Responsiveness   Floor and ceiling effects   Interpretability
  --------------- -------------------------------------------------------- ------------------ ---------------------- -------------------- -------------------- ----------------------------- ------------------------------- ---------------- --------------------------- ------------------
  SAHD            Rosenfeld, 1999^[@bibr21-0269216316669867]^              \+                 \+                     \+                   \+                   0                             0                               0                \+                          0
  SAHD            Rosenfeld, 2000^[@bibr24-0269216316669867]^              \+                 \+                     −                    ?                    0                             0                               0                \+                          0
  Modified DDRS   Kelly, 2002^[@bibr1-0269216316669867]^                   \+                 \+                     0                    0                    0                             0                               0                0                           0
  SAHD            Mystakidou, 2004^[@bibr25-0269216316669867]^             \+                 \+                     0                    0                    \+                            \+                              0                \+                          0
  SISC            Wilson, 2004^[@bibr33-0269216316669867]^                 \+                 0                      \+                   ?                    ?                             −                               0                0                           0
  SAHD            Shim, 2011^[@bibr13-0269216316669867]^                   \+                 −                      0                    0                    0                             0                               0                0                           0
  SAHD            Villavicencio-Chávez, 2014^[@bibr15-0269216316669867]^   \+                 \+                     0                    \+                   0                             0                               0                0                           0
  SAHD            Galushko, 2015^[@bibr26-0269216316669867]^               \+                 \+                     −                    ?                    0                             0                               0                0                           0

DDRS: Desire for Death Rating Scale; SAHD: Schedule of Attitudes toward Hastened Death; SISC: Structured Interview for Symptoms and Concerns.

Rating: +: positive (the study by Terwee et al.^[@bibr60-0269216316669867]^ specifies criteria for determining whether the quality of each measurement property can be regarded as positive or negative); ?: indeterminate (doubtful information regarding each psychometric property); −: negative; 0: no information available. For more detailed information regarding the quality criteria for measurement properties of health status questionnaires, see Terwee et al.^[@bibr32-0269216316669867]^ ([Table 1](#table1-0269216316669867){ref-type="table"}, p. 39).

Discussion {#section20-0269216316669867}
==========

This systematic review analysed 50 articles reporting the assessment of the WTHD in patients with advanced disease (which has recently defined by the Coalition to Transform Advanced Care as 'when one or more conditions become serious enough that general health and functioning decline, and treatments begin to lose their impact'^[@bibr63-0269216316669867]^). We identified and analysed seven instruments of measurement (five different instruments, plus two modified versions of one of these) that have been used for this purpose, the assessment of WTHD in patients with advanced disease.

The review reveals that three instruments^[@bibr22-0269216316669867],[@bibr34-0269216316669867],[@bibr35-0269216316669867]^ were developed by authors for a specific study and they have not subsequently been used in other published researches. By contrast, instruments such as the DDRS^[@bibr20-0269216316669867]^ and, especially, the SAHD^[@bibr21-0269216316669867]^ have been widely used. One aspect that is often lacking, however, is an explicit description of the theoretical framework that guided the development of an instrument, or specific details regarding the construct that the authors are seeking to measure. This lack of conceptual clarity appears to have led to the development of different assessment methods that focus on different aspects of the phenomenon, with the scope of this focus varying from one instrument to another.

Despite these differences, however, a characteristic common to all the instruments is the idea that the WTHD can be understood as a reaction to suffering.^[@bibr1-0269216316669867],[@bibr20-0269216316669867],[@bibr21-0269216316669867],[@bibr33-0269216316669867],[@bibr35-0269216316669867]^ Items referring explicitly to suffering feature in four of the instruments analysed, namely, the original and the two modified versions of the DDRS,^[@bibr1-0269216316669867],[@bibr20-0269216316669867],[@bibr33-0269216316669867]^ and the SAHD.^[@bibr21-0269216316669867]^ Although the items used in the other instruments^[@bibr22-0269216316669867],[@bibr34-0269216316669867],[@bibr35-0269216316669867]^ do not make explicit reference to suffering, the authors do, in their analysis of results, link the WTHD to the presence of intense suffering.

The difficulty of defining the construct of the WTHD is one of the main limitations associated with the instruments analysed. For example, the problem of how to discriminate between a 'genuine' WTHD and simply the acceptance of death in an end-of-life context is mentioned in a number of studies, mainly with respect to the SAHD.^[@bibr6-0269216316669867],[@bibr15-0269216316669867],[@bibr22-0269216316669867],[@bibr39-0269216316669867]^ The authors of this instrument suggest using a cut-off score ⩾10 (range, 0--20) as a way of overcoming this potential problem,^[@bibr6-0269216316669867]^ although the decision as to whether a lower or higher cut-off should be used will ultimately depend on the specific research objectives.^[@bibr21-0269216316669867],[@bibr24-0269216316669867]^ The variable or arbitrary nature of the cut-off scores used in different studies is an issue that also affects the DDRS. These differences in cut-off scores are one of the aspects that make it difficult to compare results across studies.

Another aspect that can be observed in several of the studies that applied one of the instruments is the relatively low proportion of patients, from among those who were eligible for inclusion, who finally participated. This reflects a common challenge faced by researchers working with vulnerable populations^[@bibr64-0269216316669867][@bibr65-0269216316669867]--[@bibr66-0269216316669867]^ and highlights the potential difficulty of conducting this kind of assessment in the clinical setting. In some of the studies that administered the SAHD, for instance, only a minority of eligible patients were ultimately able to participate: in three studies conducted in the United States,^[@bibr49-0269216316669867],[@bibr51-0269216316669867],[@bibr54-0269216316669867]^ between 13% and 26% of eligible patients provided analysable data, while the corresponding figure in studies conducted in Germany^[@bibr61-0269216316669867]^ and Spain^[@bibr15-0269216316669867]^ was 31% and 35%, respectively. It should be noted, however, that this instrument (the SAHD) was originally developed for use in research rather than in clinical practice.^[@bibr21-0269216316669867]^

The DDRS, by contrast, was designed for clinician administration in the context of a clinical interview, and this may account for the higher rates of patient participation observed in studies that have used this instrument. In 6 of the 14 studies^[@bibr16-0269216316669867],[@bibr20-0269216316669867],[@bibr38-0269216316669867],[@bibr41-0269216316669867],[@bibr44-0269216316669867],[@bibr46-0269216316669867]^ that provide such data, participation was ⩾60%, and in no case was it below 37%. With respect to the other instruments used to assess the WTHD, participation rates never exceeded 65%.

Regarding the study population, the review shows that participation rates were highest (\>60%) in studies involving non-oncology populations,^[@bibr16-0269216316669867],[@bibr34-0269216316669867],[@bibr35-0269216316669867],[@bibr41-0269216316669867]^ for which reported rates were 25%--35% higher than in samples of patients with cancer, who were generally in the advanced or terminal stage of the disease.

In terms of the methodological quality of validation studies that examined the measurement properties of an instrument, we found that the data reported in most cases meant that only some of the criteria could be evaluated. This lack of information regarding some properties is a common problem faced by systematic reviews of measurement instruments.^[@bibr67-0269216316669867][@bibr68-0269216316669867][@bibr69-0269216316669867][@bibr70-0269216316669867]--[@bibr71-0269216316669867]^ None of the instruments identified was investigated using IRT, an approach that would perhaps enable a more specific examination of item adequacy, as well as the establishment of a risk score for the WTHD.^[@bibr72-0269216316669867]^ Regarding the adequacy of the psychometric properties of the instruments considered, more information than is reported by the articles would be required in order to state categorically whether or not the different measures show adequate properties in terms of COSMIN criteria. The difficulty of evaluating all the quality criteria needs to be seen in the context of sample characteristics, that is, patients with advanced disease and short survival.

Strengths and limitations of this review {#section21-0269216316669867}
----------------------------------------

A strength of this review is that studies were selected independently by two researchers, thus minimising the possibility of selection errors. Furthermore, the methodological quality of studies that examined measurement properties was assessed by means of specific instruments of reference,^[@bibr30-0269216316669867],[@bibr32-0269216316669867]^ such that the results can be regarded as objective. We also believe that by describing the wide range of instruments available in the context of advanced disease, this review provides both clinicians and researchers with an overview of these tools and allows them to consider their strengths and limitations.

In our view, the difficulty of reviewing such a varied set of articles ultimately constitutes one of the contributions of this report. We have managed to synthesise an extensive body of information, although the diverse range of designs used by studies that describe instruments undoubtedly makes comparison difficult.

The lack of an agreed conceptual framework for defining the WTHD poses a challenge when it comes to studying specific clinical aspects of this phenomenon. In this respect, it should be noted that a recent study involving a nominal group and an international Delphi process has proposed a consensus definition of the WTHD,^[@bibr73-0269216316669867]^ one which could serve as a platform for the future design and evaluation of instruments to assess the WTHD.

Due to the inclusion criteria for this review, the results are applicable only to adults. We acknowledge, however, that the WTHD has also been studied in the paediatric population,^[@bibr74-0269216316669867]^ as well as in the elderly in general.^[@bibr75-0269216316669867],[@bibr76-0269216316669867]^ We also excluded two studies that, despite examining the WTHD in a palliative care setting, did so on the basis of patients' spontaneous expression of such a wish, rather than through application of an instrument. This was the case of the study by Güell et al.,^[@bibr77-0269216316669867]^ who used a semi-structured interview to explore the reasons behind the desire-to-die statements made by terminally ill cancer patients. Similarly, Freeman et al.^[@bibr78-0269216316669867]^ studied a sample of palliative home care patients who had voluntarily expressed the wish to die to relatives, friends or clinical staff. Finally, we excluded a study regarding the desire to die or for hastened death among Japanese palliative care patients because the data were derived from a survey of the patients' families.^[@bibr9-0269216316669867]^

In summary, seven different instruments have been used for the measure of the WTHD. The SAHD and the DDRS (including its modified versions) are the instruments that have been most widely used to assess the WTHD, with one or the other featuring in 48 of the 50 studies reviewed. Unfortunately, the data regarding their measurement properties are limited and do not enable us to establish the superiority of one instrument over the other. However, if their characteristics are considered alongside those of the studies in which they have been used, it appears that the DDRS is more geared towards clinical practice, whereas the SAHD is perhaps best suited to research. In fact, the DDRS, which comprises just four questions that readily yield a total score, has been applied exclusively in the clinical context, whereas the SAHD was originally designed as a self-report research tool^[@bibr21-0269216316669867]^ and may be too long (20 items) for routine clinical use. Furthermore, some aspects of the SAHD, such as its direct wording, may make it less suitable for patients who are physically and/or emotionally fragile; it is worth noting in this regard that some authors have chosen to use it as a clinician-administered tool subsequent to adequate preparation of patients.^[@bibr15-0269216316669867],[@bibr26-0269216316669867]^ Nonetheless, the SAHD remains the most widely used instrument to date, and the one whose psychometric properties have been most often analysed. Versions of this instrument are currently available in five languages other than the original English.

The prevalence data for the WTHD obtained through application of the SAHD and the DDRS reveal, in both cases, considerable variability across studies. In samples of palliative care patients with advanced and/or terminal disease, rates are between 3.3% and 20% for the DDRS and between 3.9% and 28% for the SAHD. However, these figures should be interpreted with caution due to methodological differences between studies with regard to sample characteristics, the percentage of eligible patients who actually participated or the study design itself.

The results of this review suggest that further studies are needed to assess the unknown measurement properties of both the SAHD and the DDRS (including its modified versions). Another point to consider is the growing awareness of the crucial role that patients themselves play in healthcare processes. In this respect, it is worth noting that for none of the seven instruments identified in this review were the views of patients explicitly gathered as a key part of the original design process or during subsequent examination of measurement properties, although some more recent studies have begun to address this issue.^[@bibr15-0269216316669867],[@bibr79-0269216316669867]^ In our opinion, this is an aspect that requires closer attention in the future.

To conclude, this systematic review provides an exhaustive analysis of the various instruments that have so far been used to assess the WTHD. It has also explored the methodological quality of validation studies that have examined the measurement properties of these instruments and offers a rating of the reported properties. We believe that the results of the review could help both clinicians and researchers in this field to choose the assessment tool that is best suited to their goals.
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